Novavax, Inc.

NasdaqGS:NVAX Stock Report

Market Cap: US$1.1b

Novavax Past Earnings Performance

Past criteria checks 0/6

Novavax's earnings have been declining at an average annual rate of -1.2%, while the Biotechs industry saw earnings growing at 20.4% annually. Revenues have been growing at an average rate of 19% per year.

Key information

-1.2%

Earnings growth rate

9.3%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate19.0%
Return on equityn/a
Net Margin-27.5%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

author-image

Sanofi Partnership And Pipeline Programs Will Expand Future Markets

Apr 22 Strategic partnerships and new vaccine programs could significantly boost Novavax's future revenue and market expansion efforts.

Novavax: Regulatory Uncertainty Creates Risk And Opportunity For Beaten-Down Vaccine Developer

Apr 11

The Market Doesn't Like What It Sees From Novavax, Inc.'s (NASDAQ:NVAX) Revenues Yet As Shares Tumble 28%

Apr 02
The Market Doesn't Like What It Sees From Novavax, Inc.'s (NASDAQ:NVAX) Revenues Yet As Shares Tumble 28%

Some Novavax, Inc. (NASDAQ:NVAX) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 12
Some Novavax, Inc. (NASDAQ:NVAX) Analysts Just Made A Major Cut To Next Year's Estimates

Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade)

Jan 16

Novavax, Inc. (NASDAQ:NVAX) Shares Fly 26% But Investors Aren't Buying For Growth

Dec 17
Novavax, Inc. (NASDAQ:NVAX) Shares Fly 26% But Investors Aren't Buying For Growth

Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target

Nov 15
Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target

Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway

Nov 13

Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues

Nov 01
Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues

Novavax Q3 Earnings A Week Away - Time To Accept A New Reality

Oct 31

Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones

Sep 01

Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business

Aug 14
Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business

Novavax: Staying Long Despite Coming Up Short In Q2

Aug 13

Novavax Ahead Of Q2 Earnings - Picking Apart The Sanofi Deal

Jul 26

Novavax: New Chapter, Questions Remain

Jun 20

Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

May 14
Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement

Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 13
Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely

May 07

Novavax: Another Day Older And Deeper In

Mar 02

Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Mar 02
Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry

Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Mar 01
Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00

Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems

Feb 23

Revenue & Expenses Breakdown

How Novavax makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:NVAX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 24682-18732421
30 Sep 24885-2854050
30 Jun 24988-2944460
31 Mar 24997-3994270
31 Dec 23984-54545741
30 Sep 231,050-5494640
30 Jun 231,597-5874790
31 Mar 231,359-1,1555050
31 Dec 221,982-65848967
30 Sep 221,847-1,3224110
30 Jun 221,291-1,4763660
31 Mar 221,403-1,3183310
31 Dec 211,146-1,7442980
30 Sep 211,204-1,0752730
30 Jun 211,182-9502520
31 Mar 21919-6151960
31 Dec 20476-4181430
30 Sep 20205-273920
30 Jun 2050-93430
31 Mar 2018-115350
31 Dec 1919-133340
30 Sep 1916-150350
30 Jun 1921-177360
31 Mar 1929-182340
31 Dec 1834-185340
30 Sep 1839-186340
30 Jun 1839-186340
31 Mar 1835-186340
31 Dec 1731-184340
30 Sep 1726-190340
30 Jun 1721-212400
31 Mar 1717-247450
31 Dec 1615-280470
30 Sep 1616-302470
30 Jun 1619-269430
31 Mar 1631-210360
31 Dec 1536-157310
30 Sep 1537-110270
30 Jun 1539-96230
31 Mar 1533-94210
31 Dec 1431-83200
30 Sep 1433-65180
30 Jun 1429-61170

Quality Earnings: NVAX is currently unprofitable.

Growing Profit Margin: NVAX is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: NVAX is unprofitable, and losses have increased over the past 5 years at a rate of 1.2% per year.

Accelerating Growth: Unable to compare NVAX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NVAX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (40.6%).

Return on Equity

High ROE: NVAX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/27 01:35
End of Day Share Price 2025/04/25 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novavax, Inc. is covered by 25 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
George ZavoicoB. Riley Securities, Inc.
Mayank MamtaniB. Riley Securities, Inc.